saad

[saad @sa21ad_]

@ilzizzo If i can buy one which one of them you recommend more and see higher rewards?

[saad @sa21ad_]

@ilzizzo Am waiting for the offering to jump in at better prices.

[saad @sa21ad_]

@ilzizzo Because approximately 45 million shares at $1.42 is nothing when you got now 135 million + previous cash + what investors bought months ago + with milestones ahead with EMA approval , all these will generate more than $200 million,exercising the warrants will not bring any good.

[saad @sa21ad_]

@ilzizzo Yeah 66 million shares is still a good thing if there is any BO or huge news and with P3 going well and drug getting approved the SP can sky rocket and we can see at least 5X from the current SP , that's why i hope they reject the warrants in any way possible.

[saad @sa21ad_]

@ilzizzo @X4Pharma @juezentexas That's what is disgusting about it warrants should be at least at $10 or so not $1.42!! Because they will take the easy gains and dump the shares and in the same time they will get their shares back below the current SP!!!

[saad @sa21ad_]

@ilzizzo @X4Pharma I didn't read the agreement but i hope that the company have the right to cancel some warrants if they feel they dont need and they are on good position financially.

[saad @sa21ad_]

@ilzizzo @X4Pharma @juezentexas That's why i hope the EMA approval comes earlier than expected and we get a huge milestone that will keep the company with good cash flow until data comes.

[saad @sa21ad_]

@blackdog_711 @ilzizzo @juezentexas I think he means it will be bought at 3-4 billion.

[saad @sa21ad_]

@PerceptiveOwl I think most investors have the 9.99% restrictions so they can't exercise the warrants unless they sell.

[saad @sa21ad_]

@ilzizzo @PerceptiveOwl I hope the EMA approval comes earlier than expected with the milestone , so the new management have no excuse to dilute specially with less than a year for the data and fast track from FDA.

[saad @sa21ad_]

@PerceptiveOwl But most warrants might be not exercised, and with EMA approval and a milestone from their partner norgine then they don't need to fully dilute.

[saad @sa21ad_]

@PerceptiveOwl This with the warrants if exercised?

[Investor Gadget 🕵️‍♂️🧬📈 @1nvestorGadget]

$XFOR $CTIC I will summarize why $XFOR now has a strong chance of success. In a previous post I predicted that Mostafa would be terminated in Q3 and Paula in either Q424 or Q126. They ended up stepping down, and not too far from my predicited departure dates.

It’s been a long week so I will attempt to keep this short. ALSO, if you like what I wrote here, please share, repost, and spread the word. This will make it easier to connect with like-minded people.

The story begins with a mendacious and deceitfully crafty CEO named, Dr. James Bianco. He founded what was called Cell Therapeutics from '91 to 2014, and retired in 2016. He specialized in burning investors cash to ashes and never turning a profit in 25 years.

Bianco acquired or in-licensed 6 cancer drugs, of which 3 were FDA approved, yet never turned in a profitable year. It had no revenue in two of the last five years of his employment, and its highest product sales during that time were $6.9mm. It also reported nearly $100 million in licensing and other revenue from 2011 to 2016, while net losses topped $500mm. Safe to say, they were hated much more by the masses than investors of X4.

His departure came at a peculiar time when the company was facing an SEC inquiry concerning disclosures over its latest drug candidate, pacritinib, which was withdrawn from a late-stage clinical trial after some patient deaths. At the time, pactrinib was in Phase III and was pulled off the shelf after a patient death that reportedly had cardiac arrest and bleeding inside the skull.

As you would anticipate, as well as Dr. Bianco, many lawsuits would follow. A headache he clearly wanted to avoid, where the unfortunate patient never had a chance. They also coincidentally forgot to disclose that Pactrinib was subpoenaed by the FDA earlier that year. They were said to have had violations of the antifraud and certain other provisions of the federal securities laws related to the Company’s disclosures concerning, among other things, the clinical test results of of the drug.

It gets worse;

[saad @sa21ad_]

@ilzizzo When will the news come out?

[saad @sa21ad_]

@ASynadino77890 @ilzizzo @X4Pharma Am really not aware of that $260 purchases.. i read somewhere that pre R/S they had 16.9 million shares at a $14 average and with the new 1.12 million shares = 33.6 pre split at 1.42 = $5.33. But if you're right and hope so it will be great news.

[saad @sa21ad_]

@ASynadino77890 @ilzizzo @X4Pharma With the new 1.12 million new shares for bain it will be as you said $5.33 but don't forget they can exercise the warrants (more stocks) so there average might go to $3 or even less but that depends on when the warrants can be exercised i hope that it is greater than $30.

[saad @sa21ad_]

@ilzizzo @X4Pharma You are telling me that even the warrants is at $1.42??? And they can use it and sell it whenever they want without any restrictions? We are totally screwed who doesn't want to exercise the 1.42 warrant when the price now is double.

[saad @sa21ad_]

@ilzizzo @X4Pharma Unfortunately don't have the old warrants i think it it was near$1.84 that's$55after R/S so it will not be exercised but for the new ones i hope it's the same because if it was less way less we will cry alot, for now without the warrants you think we will be around25mill shares?